Traders should monitor upcoming EFS analyses in 2027–2028 as key value inflection points. The strong safety and efficacy signal in a pivotal setting boosts confidence in Cellectis's platform and its financial upside, making this a potential catalyst for re-rating despite current pre-revenue status.
Price Chart
Executive Summary
Cellectis highlighted positive interim futility data from Allogene's pivotal ALPHA3 trial for cema-cel, an allogeneic CAR-T therapy licensed to Servier and sublicensed to Allogene. The data showed a 41.6% absolute improvement in MRD negativity versus observation, with strong safety and outpatient manageability, supporting potential clinical benefit and future BLA submission. As the originator of the UCART19 platform, Cellectis stands to benefit from up to $340 million in milestones and low double-digit royalties.
Key Facts
- Interim futility analysis from Allogene's pivotal ALPHA3 trial showed 58.3% (7/12) MRD negativity in the cema-cel arm vs. 16.7% (2/12) in the observation arm, a 41.6% absolute difference.
- Cema-cel was well-tolerated: no CRS, ICANS, GvHD, or treatment-related SAEs; 10/12 patients managed outpatient post-infusion.
- Study accrual expected by end of 2027; interim EFS analysis mid-2027, primary EFS analysis mid-2028; positive results could support BLA submission.
- Cema-cel is derived from Cellectis's UCART19 platform, licensed to Servier under an agreement that entitles Cellectis to up to $340M in development and sales milestones and low double-digit royalties on net sales.
- This is a pivotal trial update for an allogeneic 'off-the-shelf' CAR-T therapy, a potentially transformative advancement over autologous CAR-Ts in terms of speed, accessibility, and consistency.
Financial Impact
Up to $340 million in potential milestone payments and low double-digit royalties on future net sales of cema-cel, though no revenue recognition yet. Market cap is $261M, so milestones represent substantial upside.
Risk Factors
- Interim data based on small patient numbers (n=24); may not predict final outcomes.
- Future results could differ due to clinical development risks, regulatory hurdles, or safety issues not yet observed.
- Cellectis is dependent on Servier and Allogene for development and commercialization; limited control over timeline and execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002410 |
| Document: f6k_041326.htm | 0001171843-26-002410 |
| Document: 0001171843-26-002410-index-headers.html | 0001171843-26-002410 |
| Document: 0001171843-26-002410-index.html | 0001171843-26-002410 |
| Document: 0001171843-26-002410.txt | 0001171843-26-002410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $1.02 (+44.26%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $1.02 (−44.26%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $1.02 (−64.02%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $1.02 (−66.00%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $1.02 (−63.96%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $1.02 (−63.96%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $1.02 (−66.99%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $1.02 (−67.92%) |
May 12, 2026 24w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $1.02 (−74.24%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $1.02 (−72.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers